Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson демонстрирует сильные финансовые показатели, но с некоторыми негативными аспектами. Мультипликаторы, такие как P/E и P/B, находятся на уровне медианы отрасли, что указывает на отсутствие явной переоцененности. Тем не менее, P/S и P/FCF значительно выше, что может свидетельствовать о переоцененности. Эффективность компании также вызывает позитивные эмоции: ROE, ROA и маржа прибыли значительно превышают медиану, что говорит о высокой рентабельности. Однако долговая нагрузка (debt/equity ratio) выше медианы, что увеличивает риски. Дивидендная доходность снизилась, что может насторожить инвесторов. В то же время, рост выручки и чистой прибыли по годам укрепляет уверенность в устойчивом финансовом состоянии компании. В целом, компания сохраняет хорошие позиции, но есть признаки потенциальной переоцененности, что может отразиться на целевой цене акций.

Johnson & Johnson

AbbVie Inc. ABBV reported first-quarter 2026 adjusted EPS of $2.65, which beat the Zacks Consensus Estimate of $2.62. The reported figure also exceeded the company’s guidance of $2.56-$2.60 issued earlier this month. Earnings rose 7.7% year over year.
ABBV’s revenues of $15.0 billion beat the Zacks Consensus Estimate of $14.78 billion. Sales rose 12.4% year over year on a reported basis and 10.3% on an operational basis. This reported figure surpassed the company’s forecast of $14.70 billion.
Revenues in the quarter were driven by robust sales of key drugs Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs, namely Ubrelvy, Qulipta, Elahere and Vyalev. Sales of Humira and Imbruvica declined year over year.
All growth rates mentioned below are on a year-on-year basis and at constant exchange rates (CER).
Immunology Drugs Drive ABBV’s Top Line
In immunology, net revenues from Rinvoq for the quarter totaled $2.12 billion, up 20.2%. The upside was likely driven by market share gains across all approved indications, as well as the recent label expansion in giant cell arteritis across the United States and the EU last year. Rinvoq’s sales beat the Zacks Consensus Estimate of $2.09 billion.
Net revenues recorded from Skyrizi were $4.48 billion, up 29.2%. This surge in sales was primarily driven by strong volume growth and continued market share gains. Skyrizi sales beat the Zacks Consensus Estimate of $4.41 billion.
AbbVie’s flagship product Humira recorded a sales decline of 40.3% to $688 million for the quarter. Sales in the United States declined 52% to $357 million, while ex-U.S. market sales were down 17.4% to $331 million. The drug’s overall sales missed the Zacks Consensus Estimate of $697 million.
This substantial decline in Humira sales was due to the drug’s loss of exclusivity in the United States since January 2023. The drug lost its exclusivity in ex-U.S. territories in 2018.
ABBV Neuroscience Drugs’ Performance
Sales from the neuroscience portfolio rose 24.3% to $2.88 billion, driven by higher sales of Botox Therapeutic, depression drug Vraylar, Parkinson's disease drug Vyalev and migraine drugs Ubrelvy and Qulipta. The franchise’s sales beat the Zacks Consensus Estimate of $2.83 billion. The reported sales numbers surpassed AbbVie’s forecast of $2.8 billion from the segment.
While Botox Therapeutic sales rose 14.9% to $1.01 billion, sales of Vraylar increased 18.4% to $905 million.
Sales of Ubrelvy totaled $339 million, up 41.2%. Qulipta sales rose 51.3% to $296 million.
Sales of Vyalev totaled $201 million, up from $183 million in the previous quarter. The drug’s sales were in line with the Zacks Consensus Estimate.
ABBV Oncology Drugs’ Performance
Sales from the oncology franchise fell 3% to $1.63 billion in the quarter. This downtick was due to declining Imbruvica sales, which more than offset the growth in sales of newer oncology drugs, Epkinly and Elahere, as well as rising Venclexta sales. Despite the decline, the metric beat the Zacks Consensus Estimate of $1.57 billion. The reported sales figure marginally surpassed the company’s guidance of $1.6 billion.
Net revenues from Imbruvica were down 24.7% to $556 million, missing the Zacks Consensus Estimate of $565 million. AbbVie markets this drug in partnership with Johnson & Johnson JNJ.
U.S. sales of J&J-partnered Imbruvica declined 37.4% to $332 million due to rising competition from novel oral treatments, as well as the IRA-driven pricing changes, which came into effect at the start of 2026. AbbVie shares international profits earned from Imbruvica with J&J. The company’s share of profit from the drug’s international sales rose 7.2% to $224 million.
AbbVie’s leukemia drug Venclexta generated revenues of $770 million in the reported quarter, reflecting growth of 9.7%. This drug’s sales beat the Zacks Consensus Estimate of $719 million. The company markets Venclexta in collaboration with Roche RHHBY.
Sales of the breast cancer drug, Elahere, rose 8.3% to $198 million. However, the metric missed the Zacks Consensus Estimate of $206 million.
Epkinly sales, which comprise AbbVie’s share of profit from U.S. revenues and product revenues from international markets, amounted to $83 million in the quarter compared with $81 million in the previous quarter. The drug is marketed in partnership with Genmab GMAB.
ABBV’s Aesthetics & Other Drugs
AbbVie’s aesthetics portfolio sales were up 5.1% to $1.19 billion, which marginally beat the Zacks Consensus Estimate of $1.18 billion. Botox Cosmetic sales rose 17% to $668 million. Juvederm sales declined 2.9% to $232 million.
While Mavyret sales rose 8.6% to $351 million, Creon sales stood at $361 million, up 1.8%. Linzess sales rose 90.9% to $283 million.
Cost Discussion
Adjusted SG&A expenses rose 3.7% year over year to $3.4 billion. Adjusted R&D expenses amounted to $2.27 billion, up 10.6%.
AbbVie Raises 2026 EPS Guidance
The company raised its EPS guidance for the full year. It expects adjusted EPS to be in the range of $14.08-$14.28, up from the previous guidance of $13.96-$14.16.
Our Take on ABBV’s Results
AbbVie’s quarterly results beat expectations. The company hiked its EPS guidance for 2026, likely driven by stronger-than-expected sales of its immunology and neuroscience products. The aesthetics franchise continued recovery in the segment after a prolonged period of soft performance, while oncology sales beat expectations despite a year-over-year decline.
Shares of AbbVie were up in pre-market trading today, likely due to the encouraging guidance update. Year to date, the stock has lost over 13% compared with the industry’s 7% decline.
Image Source: Zacks Investment Research
The neuroscience franchise continues to gain traction, supported by newer assets like Ubrelvy, Qulipta and Vyalev. Strong sales of Linzess and Mavyret helped offset weakness in Humira and Imbruvica.
To offset the declines from its legacy products, AbbVie is strengthening its long-term growth platform through M&A activity and internal innovation. The recent regulatory filing to expand Rinvoq’s label into alopecia areata further supports its strategy of driving sustained growth through additional immunology indications.
The FDA is currently reviewing the company’s filings — one for pivekimab sunirine (PVEK) to treat a rare and aggressive blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN) and another for tavapadon in early Parkinson’s disease. Both assets, added through prior acquisitions, could serve as additional growth drivers if approved.
AbbVie Inc. Price
ABBV’s Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ABBV Beats on Q1 Earnings & Sales, Raises '26 EPS View

GSK plc GSK reported first-quarter 2026 core earnings of $1.26 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings rose 4% year over year on a reported basis and 9% at a constant exchange rate (CER), driven by higher sales turnover, favorable product mix and higher royalty income during the quarter.
Quarterly revenues rose 2% on a reported basis and 5% at CER to $10.30 billion (£7.63 billion). This upside was attributed to the rising sales of its HIV, oncology and respiratory medicines. The top line also beat the Zacks Consensus Estimate of $10.19 billion.
All growth rates mentioned below are on a year-over-year basis and at CER.
GSK’s Q1 Segmental Discussion
GSK reports under three segments — General Medicines, Specialty Medicines and Vaccines. While sales in the Specialty Medicines increased 14%, the Vaccine segment rose 4%. Sales in the General Medicines segment, however, declined 6% on a year-over-year basis.
GSK’s Specialty Medicines Aid Top Line
HIV Sales
HIV sales rose 10% in the first quarter of 2026, driven by an increase in patient demand for Dovato as well as long-acting medications, Apretude and Cabenuva. Sales in the quarter also benefited from favorable pricing due to channel mix, which offset the impact of regional pricing pressures.
GSK generates the majority of its HIV sales from its dolutegravir franchise, comprising two-drug regimens — Dovato and J&J JNJ-partnered Juluca — and three-drug regimens — Triumeq and Tivicay.
Dovato sales rose 20%, while those of the J&J-partnered Juluca declined 3%.
Tivicay sales rose 2% during the quarter, while those of Triumeq fell 27%.
Sales of Apretude and Cabenuva rose 44% and 31%, respectively. These two long-acting medicines currently account for more than a quarter of HIV sales.
Oncology Sales
Oncology sales rose 28%, driven by strong demand for Jemperli, Ojjaara/Omjjara and Blenrep.
Jemperli sales rose 40% during the first quarter, driven by increased patient uptake across the United States and Europe following the drug’s label expansion to treat all adult patients with primary advanced or recurrent endometrial cancer.
Sales of the blood cancer drug Ojjaara/Omjjara rose 34%, primarily driven by strong patient uptake and continued commercial launches across Europe and international markets. U.S. volume growth was partly offset by ongoing pricing pressures.
Zejula sales fell 11% in the quarter due to increased competition in Europe and significant volume reduction in the United States.
Respiratory, Immunology & Inflammation Sales
Respiratory, Immunology & Inflammation sales increased 16%, driven by Nucala and Exdensur in respiratory and Benlysta in immunology.
Sales of the respiratory drug Nucala were up 12% during the quarter, mainly driven by strong performance across all markets, especially the United States, where the drug recently received label expansion in the COPD indication. This upside was partially offset by continued pricing pressures and channel mix impacts.
Sales of the immuno-inflammation drug Benlysta were up 13% in the quarter, reflecting strong product demand across all marketed territories.
GSK’s Vaccine Sales Up
In Vaccines, sales growth was mainly driven by increased uptake of shingles vaccines in Europe, partly offset by lower sales of Other Paediatric & Adult vaccines.
Sales of the company’s shingles vaccine, Shingrix, rose 20% during the quarter, driven by strong growth, especially in Europe and the United States, as well as favorable channel inventory movement. Lower sales in international markets partially offset this growth.
In Meningitis vaccines, sales of Bexsero rose 5%, while Menveo sales were down 25%. Sales of the RSV vaccine, Arexvy, plunged 18% during the quarter, due to slower market demand in the United States.
Influenza vaccine sales rose more than 100% during the quarter.
Sales of Other Paediatric & Adult vaccines (previously known as Established vaccines) fell 9%, owing to competitive pressure for Synflorix, primarily in Emerging Markets and lower sales for Hepatitis, Boostrix and Infanrix/Pediarix vaccines in the United States and international markets.
GSK’s General Medicines Fall
In this segment, Anoro Ellipta sales increased 2%, while sales of Relvar/Breo Ellipta declined 12%. Ventolin sales declined 19%.
While Advair/Seretide sales declined 11%, sales of Flixotide/Flovent increased 35%.
Trelegy Ellipta was flat year over year during the quarter. U.S. sales declined due to Medicare benefit design changes and unfavorable pricing and channel mix. Strong volume growth in Europe and international markets was driven by patient demand.
Operating Expenses
Core selling, general and administration costs declined 2% to £1.98 billion, driven by ongoing productivity initiatives and net legal settlements and expenses.
Core research and development expenses rose 12% to £1.49 billion. This uptick highlights the company’s continued investment in pipeline development.
GSK Maintains 2026 Guidance
GSK reiterated its total revenue guidance for 2026, which it had provided earlier this year. The company continues to expect sales to increase 3-5% during the year.
GSK expects sales of Specialty Medicines to increase by a low double-digit percentage at CER in 2026. However, management forecasts sales across the General Medicines and Vaccines franchises to either decline by a low single-digit percentage or remain broadly stable.
GSK expects both core operating profit and core EPS to grow in the range of 7-9%.
R&D is expected to increase at a rate slightly higher than sales growth, while SG&A is expected to grow at a low single-digit percentage. The adjusted tax rate is expected to be around 17.5%.
Our Take on GSK’s Results
GSK reported better-than-expected first-quarter results, driven by strong demand for its Specialty Medicines portfolio. Growth in the Vaccines business also helped offset weaker sales in the General Medicines segment. Although U.S. sales were partly impacted by continued pricing pressures from the Medicare Part D redesign, softer demand for Arexvy, and flat sales of Trelegy Ellipta, these headwinds were more than offset by higher demand for other products, including Dovato, Cabenuva, Apretude, Jemperli, Ojjaara/Omjjara and Nucala.
GSK maintained its outlook for full-year 2026. The company also reiterated its outlook for 2031, expecting to generate sales of more than £40 billion.
Despite the better-than-expected results, shares of GSK were trading down in pre-market today.
The stock has increased 11% year to date against the industry’s decline of 1.6%.
Image Source: Zacks Investment Research
In 2026, GSK expects two major product approvals — Ionis Pharmaceuticals IONS-partnered bepirovirsen for chronic hepatitis B and Spero Therapeutics SPRO-partnered tebipenem for complicated urinary tract infections. Tebipenem and bepirovirsen are currently under review in the United States, with a decision expected in the first half and second half of 2026, respectively.
GSK PLC Sponsored ADR Price, Consensus and EPS Surprise
GSK’s Zacks Rank
GSK currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

Investment banker Goldman Sachs recently raised its price target for UnitedHealth Group Incorporated (UNH) shares from $400 to $435, citing the company’s increased full-year guidance, announced in its latest quarterly results release, as evidence of UnitedHealth’s long-term earnings growth potential (as cited in Investing.com).
Notably, Goldman Sachs expects UnitedHealth to return to at least 13% to 16% earnings per share growth over the next several years as it executes its business recovery.
While this upgrade, following UNH’s recently released better-than-expected first-quarter 2026 results, may tempt investors to add the stock to their portfolios immediately, a significant headwind remains on the horizon. Legislative changes enacted last year have led to major funding cuts in Medicaid for 2026, putting UNH’s Medicaid business under intense margin pressure. In fact, the company’s management has already signaled expectations for membership attrition and negative margins within this specific segment throughout the year.
However, for those who want to gain exposure to UnitedHealth’s growth while mitigating the idiosyncratic risks of its Medicaid business, diversified healthcare exchange-traded funds (ETFs) offer a more prudent path. By investing in funds where UNH is a top-10 holding, investors benefit from the company's strong medical cost management and declining medical care ratio (which improved to 83.9% in the first quarter), while spreading risk across other healthcare giants in pharma, biotech and medtech industries.
Before suggesting a few such ETFs for your portfolio, let’s take a detailed look at UnitedHealth’s first-quarter performance across key metrics and how analysts from different firms reacted to this result to get a hint of the whole picture.
A Brief Analysis of UNH’s Q1 Results
UnitedHealth’s first-quarter adjusted earnings per share (EPS) surpassed the Zacks Consensus Estimate by 11.9%, while its revenues beat the consensus mark by 2.1%. On a year-over-year basis, the company delivered a solid performance on both counts.
Its first-quarter operating cost ratio came in at 13.8%, up year over year from 12.4%, reflecting the timing of targeted investments across operations, technology and care delivery as well as incremental investments in areas such as AI, customer experience, cybersecurity and community engagement.
UNH was successful in bringing its debt-to-capital ratio down to 42.9% by the end of the first quarter and remains on track to end this year with its goal of achieving a 40% debt-to-capital ratio.
From the viewpoint of the share buyback program, the company initiated share repurchases earlier than anticipated and expects to deploy at least $2 billion by the end of the second quarter of 2026.
As far as its Optum Rx business is concerned, UnitedHealth started 2026 by onboarding more than 800 new clients, while reducing contact call center volume 25% through enhanced digital and AI-enabled self-service, with member satisfaction reaching more than 95%.
Within areas like consumer member experience, UNH recently launched Avery, a generative AI chatbot answering member questions for UnitedHealthcare. The company aims to expand this chatbot to include over 20 million members by the end of 2026.
Meanwhile, Optum Real, an AI-first platform that UNH launched a couple of quarters ago, now has 0.5 billion transactions year to date, with the company expecting to close the year at over 2.5 billion transactions.
Analysts’ Reactions
Following UNH’s Q1 results, analysts from varied firms, apart from Goldman Sachs, have upgraded their price target for this stock, showing renewed optimism in its progress.
For example, Morgan Stanley recently raised its price target on UNH from $375 to $395, while maintaining its “Overweight” rating. Other renowned institutions like Deutsche Bank raised its price target on UnitedHealth from $304 to $360, while maintaining a Hold rating, following the company’s first-quarter results.
UNH-Heavy ETFs to Watch
iShares U.S. Healthcare Providers ETF IHF
This fund, with net assets worth $738.8 million, provides exposure to 60 U.S. companies that provide health insurance, diagnostics and specialized treatment. Of these, UnitedHealth Group takes the first spot, accounting for a 26.50% share. CVS Health CVS (12.49%) and HCA Healthcare (7.38%) hold the second and third positions in this fund, respectively.
IHF charges 38 basis points (bps) in fees. It traded at a good volume of 1.24 million shares in the last trading session.
iShares U.S. Healthcare ETF IYH
This fund, with net assets worth $2.84 billion, provides exposure to 103 U.S. healthcare equipment and services, pharmaceuticals, and biotechnology companies. Of these, UnitedHealth Group takes the fourth spot, accounting for a 5.99% share. Pharma giants Eli Lily LLY (13.12%), Johnson & Johnson JNJ (10.15%) and AbbVie ABBV (6.52%) hold the top three spots in this fund.
IYH charges 38 bps in fees. It traded at a volume of 0.40 million shares in the last trading session.
Vanguard Health Care ETF VHT
With net assets of $16.2 billion, this fund provides exposure to 407 companies engaged in health care equipment manufacturing, health care services, and the research, development, and marketing of pharmaceuticals and biotechnology products. Of these, UnitedHealth Group takes the fifth spot, accounting for a 3.94% share. LLY (11.89%), JNJ (9.34%) and ABBV (6.18%) hold the top three spots in this fund.
VHT charges 9 bps in fees. It traded at a volume of 0.28 million shares in the last trading session.
Boost Your Portfolio with Our Top ETF Insights
Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.
Don’t miss out on this valuable resource. It’s free!
Get it now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
iShares U.S. Healthcare ETF (IYH): ETF Research Reports
iShares U.S. Healthcare Providers ETF (IHF): ETF Research Reports
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Goldman Sachs Lifts UnitedHealth Target Price: Healthcare ETFs to Watch

Key Points
Bristol Myers Squibb's valuation metrics show the stock is a bona fide bargain.
However, valuation metrics can be misleading because most of them don't factor in growth.
The stock may not be the biggest bargain in Big Pharma, but it could still be attractive to income and value investors.
Every American knows that healthcare isn't cheap. Healthcare costs continue to rise. Some healthcare stocks are cheap, though, including the stocks of some of the world's biggest drugmakers.
Bristol Myers Squibb (BMS) (NYSE: BMY) is one of them. To be sure, BMS isn't the biggest pharma stock. Its market cap of around $120 billion ranks it just outside the top 10 largest drugmakers. But is BMS the best bargain in big pharma?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Some persuasive numbers
A quick look at BMS's valuation metrics might convince you that this stock is a bona fide bargain. For example, the average price-to-sales ratio for pharmaceutical companies is around 4.4. BMS's shares trade at only 2.5 times sales.
The company's bottom line appears to scream "bargain", too. BMS's forward price-to-earnings ratio is a low 9.4. The healthcare sector's average forward earnings multiple is 17.3.
Some investors prefer to use enterprise value (EV) to value companies because it accounts for debt. BMS's EV/EBITDA multiple of 10.3 also looks attractive compared to most other drugmakers. Lilly is super-expensive with its EV/EBITDA of around 27. AbbVie (NYSE: ABBV), AstraZeneca (NYSE: AZN), and Johnson & Johnson (NYSE: JNJ) also sport much higher EV-based multiples than BMS.
What about a deeper dive into BMS's valuation? At least one discounted cash flow model estimates that the pharma stock is significantly undervalued, with an upside of roughly 40%.
Valuation metrics can be misleading
BMS looks like a value stock from nearly every angle. However, valuation metrics can be misleading. Specifically, most of them don't account for a company's growth prospects over the next several years. Unfortunately, BMS's growth will almost certainly slow drastically.
The company faces a daunting patent cliff. U.S. patents for blood thinner Eliquis and cancer immunotherapy Opdivo expire in 2028. Last year, Eliquis was BMS's top-selling drug, while Opdivo ranked No. 2. Their combined sales make up nearly half of the company's total revenue.
BMS won't have to wait until its top two blockbusters lose exclusivity to encounter problems. Cancer drugs Abraxane, Pomalyst, Revlimid, and Sprycel have already lost patent exclusivity. The company expects revenue to decrease slightly this year compared to 2025.
Stocks are usually cheap for a reason. BMS is no exception. Investors have given the stock a low valuation because they know the growth prospects aren't appealing over the rest of the decade.
Granted, BMS has a promising growth portfolio that includes cancer drug Opdualag, autoimmune disease drug Sotyktu, and heart disease drug Camzyos. Combined sales from all of the drugs in the company's growth portfolio rose 17% year over year in 2025. However, BMS's legacy drugs still comprise roughly 45% of revenue.
The biggest bargain in big pharma?
Probably the best argument against Bristol Myers Squibb being the biggest bargain in big pharma is that several other stocks have even lower valuation metrics. Pfizer (NYSE: PFE), for example, boasts a lower forward P/E multiple of 9.1. Factoring in growth projections over the next five years, AbbVie looks more attractively valued.
However, BMS doesn't have to be the biggest bargain in big pharma to still be a good pick for some investors. Many income investors will love the company's forward dividend yield of 4.3% and its record of increasing dividends for 17 consecutive years. A lack of growth won't be as concerning to most income investors. As long as BMS can keep the dividends flowing, they'll be happy.
Some value investors may still find BMS appealing, especially those with long investment horizons. The company's growth portfolio should steadily generate a larger share of its revenue. BMS CEO Chris Boerner believes that his company has "the potential to achieve industry-leading, sustainable growth into the 2030s and beyond." If you're willing to wait, BMS could deliver solid total returns.
Should you buy stock in Bristol Myers Squibb right now?
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 27, 2026.
Keith Speights has positions in AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool has positions in and recommends AbbVie, AstraZeneca Plc, Bristol Myers Squibb, and Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is Bristol Myers Squibb the Best Bargain in Big Pharma?

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Bahl & Gaynor Income Growth ETF (Symbol: BGIG) where we have detected an approximate $182.5 million dollar inflow -- that's a 8.5% increase week over week in outstanding units (from 61,962,547 to 67,242,547). Among the largest underlying components of BGIG, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.9%, PNC Financial Services Group (Symbol: PNC) is off about 1.3%, and JPMorgan Chase & Co (Symbol: JPM) is lower by about 0.7%. For a complete list of holdings, visit the BGIG Holdings page » The chart below shows the one year price performance of BGIG, versus its 200 day moving average:
Looking at the chart above, BGIG's low point in its 52 week range is $28.4305 per share, with $34.8828 as the 52 week high point — that compares with a last trade of $34.44. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Project your dividend income with confidence: Income Calendar tracks your income portfolio like a personal assistant.
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Advertising Dividend Stocks
BSJT market cap history
Cheap Consumer Shares
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

BGIG, JNJ, PNC, JPM: ETF Inflow Alert

(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Wilson's Disease, Ovarian cancer and stiff person syndrome.
Let's unpack the specifics.
FDA and EU Approvals & Rejections
Sanofi (SNY) won expanded FDA approval for Tzield?in stage 2 type 1 diabetes, now covering children as young as one year old. The CD-3-directed antibody remains the only therapy to delay progression to stage 3 disease, with the decision supported by the PETITE-T1D Phase 4 study.
SNY closed Thursday's trading (April 24, 2026) at $47.53, up 1.34%.
Royal Philips (PHG)?received U.S. FDA 510(k) clearance for its Rembra platform, including Rembra CT, Rembra RT, and Areta RT system. The technologies aim to expand access to faster, more precise imaging across frontline care and cancer treatment planning, with features such as an 85 cm bore and high-throughput capacity supporting up to 270 exams per day. The clearance strengthens Philips' diagnostic imaging and radiation oncology portfolio.
PHG closed Thursday's trading at $27.63, down 2.16%.
Sanofi (SNY) and Regeneron secured FDA approval for Dupixent?to treat children aged 2-11 with chronic spontaneous urticaria who remain symptomatic and uncontrolled by antihistamines. The decision, based on LIBERTY-CUPID data, expands Dupixent's reach beyond adults and adolescents, marking its ninth approved indication across allergy-related conditions.
SNY closed Thursday's trading at $47.53, up 1.34%.
Alpha Tau Medical Ltd. (DRTS) received FDA approval for an IDE supplement, allowing expansion of its IMPACT pilot study of Alpha DaRT in pancreatic cancer to include patients treated with Gemcitabine with Abraxane. The intratumoral alpha-radiation therapy is now being evaluated alongside both leading first-line chemotherapy regimens, broadening its development path in unresectable and metastatic disease. Enrolment is expected to complete in Q3 2026.
DRTS closed Thursday's trading at $7.98, down 1.24%.
Cipla Wins FDA Nod for the First Generic Ventolin HFA
Cipla Limited (CIPLA) and its U.S. subsidiary received FDA approval for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation, the first AB-rated generic of Ventolin HFA. Indicated for bronchospasm?and?exercise induced bronchospasm in patients aged four and older, the approval strengthens Cipla's U.S. respiratory portfolio and expands its leadership in inhalation therapies. The product will be manufactured at Cipla's new inhalation facility in Massachusetts
CIPLA closed Thursday's trading at INR 1,295.00, down 0.83%.
Regeneron Pharmaceuticals (REGN) secured FDA accelerated approval for Otarmeni, the first gene therapy for genetic hearing loss linked to OTOF gene variants. The decision, supported by pivotal CHORD trial data, makes Otarmeni available at no cost to clinically eligible U.S. patients. The therapy uses an adeno-associated virus vector to restore hearing in pediatric and adult patients with severe sensorineural?loss.
REGN closed Thursday's trading at $766.02, up 2.60%.
AbbVie (ABBV) announced it received a Complete Response Letter from the FDA for its Biologics License Application for TrenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines, citing manufacturing process issues. The agency did not raise safety or efficacy concerns and did not request additional clinical studies. AbbVie plans to submit a comprehensive response in the coming months.
ABBV closed Thursday's trading at $200.95, up 0.22%.
Grace Therapeutics, Inc. (GRCE)?received a Complete Response Letter (CRL) for its NDA of GTx-104, an IV Nimodipine?formulation for aneurysmal subarachnoid haemorrhage (aSAH). The agency cited chemistry, manufacturing, and non-clinical deficiencies, including packaging and toxicology data, but did not question efficacy. Grace plans to resubmit after addressing the issues, supported by Phase 3 STRIVE-ON trial data showing reduced hypotension versus oral Nimodipine.
GRCE closed Thursday's trading at $2.35, down 45.48%.
Deals
Vystar Corporation (VYST) has entered into a binding letter of intent to acquire a 50% interest in R3alm Inc., a compliance-focused AI and Web3 financial ecosystem.
Under the proposed transaction, R3alm would receive approximately 8,500 shares of Vystar Series B preferred stock, and both parties would jointly manage and develop the platform. Closing is expected within 60 days, subject to approval conditions.
VYST closed Thursday's trade at $0.33, up 3.13%.
Eli Lilly and Company (LLY) and Kelonia Therapeutics, Inc., announced a definitive agreement for Lilly to acquire Kelonia and Kelonia shareholders will receive up to $7 billion in cash, including an upfront payment of $3.25 billion and subsequent payments upon achievement of certain clinical, regulatory, and commercial milestones.
The acquisition may expand Lilly's genetic medicine capabilities with in vivo gene delivery and integration technology. The transaction is expected to close in the second half of 2026, subject to conditions.
LLY closed Thursday's trade at $917.65, down 0.42%
QuidelOrtho Corporation (QDEL), a diagnostics company, announced that it has completed the acquisition of LEX Diagnostics, the developer of the FDA-cleared LEX VELO system, for a cash consideration of approximately $100 million.
QuidelOrtho stated that the acquisition of LEX would accelerate growth in its point-of-care molecular diagnostics market, and the company anticipates launching the LEX VELO system in the U.S. later this year, with global expansion planned.
QDEL closed Thursday's trade at $11.24, down 5.55%.
Amneal Pharmaceuticals, Inc. (AMRX), a generic medicine and biosimilar manufacturer, announced that it has entered into a definitive agreement to acquire Kashiv BioSciences in a transaction that includes $375 million of cash and $375 million of equity payable at closing and up to $350 million in potential regulatory milestones and royalty payments.
The transaction positions Amneal to capitalise on more than $300 billion in global biologic drug sales expected to lose exclusivity over the next decade.
The transaction is expected to close in the second half of 2026, subject to approval conditions.
AMRX closed Thursday's trade at $12.65, down 1.33%.
Genenta Science S.p.A. (GNTA)?has signed a definitive agreement to acquire a controlling stake in Sòphia High Tech S.r.l., a manufacturer of precision mechanical components used in European space and defence programs
As per the agreement terms, Genenta will invest 6.0 million euros in two tranches. The first tranche will give the company a 19.9% stake, while completion of the second tranche will increase ownership to 51%, making Sophia High Tech a majority-owned subsidiary.
GNTA closed Thursday's trade at $0.70, down 1.69%.
Clinical Trials - Breakthroughs & Setbacks
Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company, announced new analyses of promising results from FoCus, a pivotal Phase 3 trial evaluating ALXN1840 (Tiomolibidate choline, TMC), an investigational oral daily treatment for Wilson Disease.
The Phase 3 FoCus trial evaluated the safety and efficacy of ALXN1840 for the treatment of Wilson disease compared with standard-of-care treatments.
ALXN1840 showed rapid and sustained copper mobilisation over 48 weeks, thus meeting its primary endpoint, and also demonstrated a favourable safety and tolerability profile across 645 patient-years of follow-up in 266 patients, with a median follow-up of 2.58 years.
MNPR closed Thursday's trading at $53.24, down 0.11%.
Kyverna Therapeutics, Inc. (KYTX), a late-stage clinical biopharmaceutical company, announced positive primary analysis results from its registrational Phase 2 trial, KYSA-8, of miv-cel (KYV-101), a CD19 CAR T-cell product candidate for stiff person syndrome.
The trial met its primary endpoint, demonstrating a statistically significant improvement in the Timed 25-Foot Walk?(T25FW) at week 16, with a median improvement of 46% from baseline.
The trial met all secondary endpoints, with significant mean improvements in mRS, HAI, DSI, and HSS of -0.8, -1.6, -1.5, and -3.2 points, respectively.
Miv-cel demonstrated a well-tolerated and manageable safety profile.
KYTX closed Thursday's trade at $9.36, up 4.53%.
Zymeworks Inc. (ZYME) presented new Phase 1 data for its folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), ZW191, demonstrating encouraging anti-tumour activity in heavily pretreated ovarian and endometrial cancers, with responses observed regardless of FRa expression levels.
In platinum-resistant ovarian cancer, ZW191 achieved a confirmed objective response rate (cORR) of 56% across all dose levels, with tumour regression in 68% of patients and disease control in 94%. At doses of 6.4-9.6 mg/kg, responses were even stronger.
Investigators noted the safety profile was manageable with no unexpected signals.
ZYME closed Thursday's trade at $27.43, down 3.38%.
Johnson & Johnson (JNJ) announced new data from the Phase 3 Vivacity-MG3 study and ongoing open-label extension in a broad population of antibody-positive adults with generalised myasthenia gravis, reinforcing the efficacy, sustained disease control and safety profile of IMAAVY.?
Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients, including anti-AChR+ and anti-MuSK+.
JNJ closed Thursday's trade at $230.65, up 2.01%.
Novo Nordisk (NVO) has reported positive topline results from the PIONEER TEENS?trial that evaluated oral Semaglutide in 132 children and adolescents aged 10-17 years with type 2 diabetes.
Oral semaglutide demonstrated a superior reduction in HbA1C, a measure of blood sugar control over placebo in the trial and showed a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.
The therapy delivered a statistically significant and superior reduction in blood sugar compared with placebo at 26 weeks, the primary endpoint.
NVO closed Thursday's trade at $38.52, down 1.61%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia

(RTTNews) - Johnson & Johnson (JNJ) has reported long-term data showing IMAAVY (Nipocalimab) maintained disease control for more than two years in adults with generalized myasthenia gravis, reinforcing its potential as a durable treatment option.
Generalised myasthenia gravis (gMG) is a chronic autoimmune condition where antibodies disrupt communication between nerves and muscles, leading to weakness, difficulties in speech swallowing, and mobility. Sustained disease control is a critical goal, as it reduces flare-ups and helps maintain daily function.
The Phase 3 Vivacity-MG3 study, followed by an open-label extension, tracked patients for up to 120 weeks. Results showed consistent improvements in muscle strength and daily living scores, with nearly one-third of patients achieving sustained minimal symptom expression (MSE)- a state where symptoms have little day-to-day impact.
Importantly, corticosteroid use was reduced in more than half of participants, and no unexpected safety concerns emerged. The most common side effects included muscle spasms, peripheral swelling, and changes in lipid levels.
A post-hoc analysis highlighted that patients who reached sustained MSE experienced greater improvements in quality of life compared to those with transient or no MSE. This patient-centric outcome underscores the therapy's potential to deliver meaningful, lasting relief.
Nipocalimab works by blocking the neonatal Fc receptor (FcRn), lowering harmful lgG antibodies while preserving essential immune functions. It is already approved in the European Union as an add-on therapy for antibody-positive gMG patients aged 12 and older. Beyond gMG, the drug is being studied in other autoimmune and maternal-fetal conditions, with several regulatory designations including FDA Fast Track and Breakthrough Therapy status.
The new findings, presented at the American Academy of Neurology 2026 Meeting, mark one of the longest follow-up periods reported for a FcRn blocker in gMG. Johnson & Johnson emphasized that these results strengthen the evidence base for Nipocalimab and highlight its role in reshaping long-term treatment strategies for patients living with this debilitating disease.
JNJ has traded between $146.12 and $251.71 over the past year. The stock closed Thursday's trading at $230.65, up 2.01%. During overnight trading, the stock is at $230.25.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Johnson & Johnson's IMAAVY Shows Two Years Of GMG Control

Shares of Spyre Therapeutics SYRE have surged 73% over the past month after the company reported encouraging data from a mid-stage study evaluating its investigational anti-α4β7 drug, SPY001, in patients with moderate-to-severe ulcerative colitis (UC).
The drug met the primary endpoint, delivering a statistically significant 9.2-point reduction in the Robarts Histopathology Index (RHI) — a key measure of tissue-level inflammation in UC — after 12 weeks of treatment. Data from the study showed that treatment with the drug achieved a 40% clinical remission rate and a 51% endoscopic improvement rate.
In addition to strong efficacy, SPY001 demonstrated a favorable safety profile that was consistent with the α4β7 class. Spyre reported that six participants experienced treatment-emergent adverse events, including one serious adverse event that was not considered drug-related. The most common side-effect was back pain.
These results come from Part A of the SKYLINE study, which is evaluating Spyre’s anti-TL1A antibody SPY002 and anti-IL-23 antibody SPY003. While Part A is an open-label phase assessing each drug individually, Part B will be a randomized, placebo-controlled stage evaluating different doses and combinations of these therapies.
Initial data from the SPY002 and SPY003 cohorts in Part A of the SKYLINE study are expected in mid-2026 and the third quarter of 2026, respectively.
What Makes SYRE’s Results So Special?
SPY001 targets the same α4β7 integrin pathway as Takeda Pharmaceutical’s TAK blockbuster drug Entyvio (vedolizumab), a well-established therapy in UC. Spyre has designed its drug with an extended half-life and optimized dosing, which may enable higher drug exposure and potentially less frequent maintenance dosing than the TAK drug, improving both efficacy and patient convenience.
This differentiated profile likely contributed to the recent surge in SYRE shares. Year to date, the stock has rallied 123% compared with the industry’s 1% growth.
Image Source: Zacks Investment Research
The company highlighted that SPY001’s efficacy compares favorably not only within the α4β7 class but against therapies across other mechanisms. In a conference call, management claimed that the efficacy data reported in the SKYLINE study were higher than those reported for either combination component in Johnson & Johnson’s JNJ mid-stage VEGA study.
This J&J study evaluated the IL-23 inhibitor Tremfya (guselkumab) and anti-TNF therapy Simponi (golimumab) as induction therapy in UC patients, aiming to improve outcomes by targeting multiple inflammatory pathways simultaneously.
Spyre Therapeutics, Inc. Price
SYRE’s Zacks Rank
Spyre currently has a Zacks Rank #4 (Sell).
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?

Black Diamond Therapeutics BDTX is building its thesis around a single, brain-penetrant EGFR inhibitor, silevertinib, with early clinical activity across a wide range of EGFR mutations and a safety profile that has been manageable and consistent with the class. The opportunity is shaped by two forces that matter in real-world treatment: resistance after prior EGFR therapy and the high clinical toll of central nervous system (CNS) disease in EGFR-mutant lung cancer.
The market is also crowded, with durable incumbents and new combination regimens raising the bar for differentiation. That pressure increases the value of clean, defensible clinical edges in defined subsets.
BDTX Fits a Growing Focus on Brain Metastases
CNS disease is a defining challenge in EGFR-mutant non-small cell lung cancer because brain metastases can be frequent and outcome-limiting. In this setting, the ability to meaningfully treat disease behind the blood-brain barrier can separate “active” from “practice-changing.”
Silevertinib was built to be brain-penetrant, positioning it to compete where many therapies struggle to deliver consistent intracranial control. If CNS activity holds with longer follow-up, it can influence how physicians think about sequencing for patients who are prone to brain involvement.
Black Diamond’s Differentiation in Non-Classical EGFR
A core point of differentiation is breadth. Silevertinib is positioned as a “family-level” EGFR inhibitor, designed to cover more than 50 classical and non-classical EGFR mutations.
That matters because non-classical mutations fragment the EGFR-mutant population into smaller subgroups. A drug that can address a broad swath of these alterations can expand the addressable opportunity without requiring a separate development program for each narrow variant.
BDTX C797S Resistance as a High-Value Opportunity
C797S is strategically important because it commonly emerges after treatment with third-generation EGFR inhibitors, creating a resistance-driven treatment gap. The absence of approved therapies in this setting turns C797S inhibition into a high-value clinical and commercial target.
Silevertinib’s ability to inhibit C797S is central to the upside case because it extends relevance beyond initial therapy and into relapse, where need is acute and options are limited. The FDA Fast Track Designation for EGFR mutant C797S-positive NSCLC progressed on or after a third-generation EGFR tyrosine kinase inhibitor reinforces the focus on this post–third-generation segment.
Black Diamond’s Early CNS Signal and What It Enables
Early CNS performance is the company’s most tangible differentiator so far. In first-line NSCLC patients with non-classical EGFR mutations, silevertinib produced a 60% objective response rate and an 86% CNS response rate, with no new safety concerns observed at the time of the update.
If durability metrics develop favorably, that kind of intracranial activity can support clinical positioning in patients at high risk for brain metastases, where prescribers often weigh CNS control heavily. The planned progression-free survival update in the second quarter of 2026 is therefore a pivotal readout for how far this signal can translate into a more durable benefit profile.
Black Diamond Therapeutics, Inc. Price and Consensus
BDTX Multi-Indication Path From NSCLC to GBM
The second leg of the story is glioblastoma. The company is advancing silevertinib into GBM on the back of what it characterized as consistent CNS activity across NSCLC and GBM studies.
The next step is a randomized phase II study in newly diagnosed GBM patients expected to begin in the first half of 2026. Interim data are anticipated in 2028, creating a longer-dated but potentially meaningful value inflection if CNS activity in lung cancer translates into a distinct signal in primary brain tumors.
Black Diamond’s Partnership Angle as a Trend Catalyst
With late-stage oncology development expensive and operationally complex, partnering can materially change perceived execution risk. For BDTX, a strategic partner could add scale for later-stage trials and broaden commercial reach if pivotal data support it.
Management has pointed to partnering as a key swing factor, alongside clinical readouts, in shaping valuation. The company is also exploring partnerships for its FGFR2/3 selective development candidate, BDTX-4876, which underscores an approach of using external capital and capabilities to extend the pipeline.
BDTX Concentration Risk in a One-Asset Story
The flip side of a focused thesis is concentration. BDTX’s valuation and long-term prospects remain heavily dependent on silevertinib, which is its only wholly owned clinical asset.
That dependence amplifies volatility around each update and makes timeline execution unusually important. Any clinical, regulatory, or development setback would have an outsized impact because there is no approved product base to offset disappointment.
Black Diamond Watchlist Through 2028
The near-term calendar centers on additional NSCLC updates in 2026, including duration of response and progression-free survival data, with the progression-free survival update expected in the second quarter of 2026. The next milestone is the initiation of the randomized phase II GBM study in the first half of 2026.
Looking further out, interim GBM data are anticipated in 2028, and the company has guided that its cash runway extends into the second half of 2028, supported by $128.7 million in cash, cash equivalents, and investments at year-end 2025. In a competitive EGFR landscape that includes AstraZeneca AZN with Tagrisso and Johnson & Johnson JNJ with the Rybrevant plus Lazcluze regimen, sustaining a differentiated CNS profile is the clearest path to stand out.
BDTX Zacks Rank
Black Diamond currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

Black Diamond Therapeutics BDTX is a clinical-stage oncology company with a story that is simple and high stakes. The upside case is tied to one drug, silevertinib, and the market’s willingness to underwrite its next data points.
Early results suggest the asset may differentiate in EGFR-mutant non-small cell lung cancer through broad mutation coverage and meaningful central nervous system activity. That focus makes 2026 execution the central swing factor for the shares.
BDTX Setup: What the Market Is Paying For
BDTX is effectively a single-asset equity. Silevertinib is the company’s only wholly owned clinical asset, and valuation is largely a function of whether upcoming milestones reinforce a differentiated profile in EGFR-mutant disease.
With no approved products, the near-term narrative is not about commercial revenue. It is about clinical durability, progression metrics, and continued evidence that the drug’s mutation coverage and brain penetration can translate into a compelling risk-benefit profile in populations where central nervous system disease is a defining problem.
Black Diamond’s Cash Runway and Funding Overhang
The balance sheet reduces immediate financing pressure but does not remove it from the debate. Black Diamond ended 2025 with $128.7 million in cash, cash equivalents, and investments and guided that liquidity into the second half of 2028.
That runway matters because it spans key catalysts, including the expected progression-free survival update in the second quarter of 2026 and additional clinical updates tied to response durability. The longer the company can fund operations without tapping the market, the more valuation can be driven by data rather than by dilution risk.
BDTX Licensing Deal With Servier and Why It Matters
The out-licensing of BDTX-4933 to Servier provided meaningful non-dilutive leverage. Under the agreement, Servier took global development and commercialization responsibility, and Black Diamond received a $70 million upfront payment in March 2025.
The structure keeps upside exposure through potential economics that scale with success. Black Diamond is eligible for up to $710 million in development and commercial milestones, plus tiered royalties on global net sales. For a company prioritizing its lead program, that kind of back-end optionality can support the funding profile without forcing the investment thesis to depend on near-term equity issuance.
Black Diamond’s Expense Reset and Loss Trajectory
Recent operating results show the impact of restructuring and portfolio focus. In fourth-quarter 2025, Black Diamond posted an adjusted net loss of $0.14 per share versus a $0.28 loss in the year-ago period, reflecting a narrower loss base.
Expense reductions were the driver. Research and development expense fell nearly 49% to $6.3 million and general and administrative expense declined about 34% to $4.0 million. Total operating expenses were $17.6 million versus $18.3 million a year earlier, even with a $7.3 million non-cash impairment charge.
BDTX Catalysts That Can Reprice the Shares in 2026
Near-term repricing hinges on whether the clinical story strengthens in ways that investors can model. The company has flagged upcoming updates on duration of response and progression-free survival as key valuation catalysts.
A key checkpoint is the expected progression-free survival data in the second quarter of 2026 for the phase II program in non-small cell lung cancer. In parallel, partnership execution remains important, with management highlighting the role of strategic collaborations as a swing factor as the lead program advances.
Black Diamond Therapeutics, Inc. Price and Consensus
Black Diamond’s Competitive Reality Check in NSCLC
Competition is a real headwind in non-small cell lung cancer, and it shapes how much differentiation BDTX must prove. AstraZeneca AZN remains a defining incumbent with Tagrisso, a widely approved third-generation EGFR tyrosine kinase inhibitor across major markets.
Johnson & Johnson JNJ also has a strengthened first-line position with FDA approval of Rybrevant in combination with Lazcluze for EGFR exon 19 deletions or exon 21 L858R substitution mutations. Against that backdrop, BDTX’s opportunity is not simply about market size. It is about whether silevertinib’s central nervous system activity and breadth across classical and non-classical EGFR mutations, including resistance like C797S, can carve out a clinically meaningful lane.
BDTX Valuation Multiples Versus Peer Benchmarks
BDTX is trading at 3.32 times forward 12-month sales value per share. That compares with 2.08 times for the Zacks sub-industry, 2.36 times for the Zacks sector, and 5.13 times for the S&P 500.
History also frames expectations. Over the past five years, the stock has traded as high as 3.96 times and as low as 1.10 times, with a five-year median of 2.06 times. For investors, that range reinforces how quickly the multiple can move when the market recalibrates the probability of success around upcoming data.
Black Diamond Decision Framework Using Zacks Metrics
BDTX carries a Neutral Zacks Rank #3 (Hold). In practice, that lines up with a wait-for-evidence approach in a story where valuation is driven by clinical milestones and partnership execution rather than recurring product sales. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Staying on the sidelines is easier to justify when the next catalyst is a definitional one, such as progression-free survival and durability updates. Taking risk ahead of data becomes more defensible only if an investor is comfortable with single-asset concentration and believes the central nervous system signal and mutation coverage will continue to hold as follow-up matures.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	26.73 21.97
Price/Sales	5.82 3.13
P/B	6.81 2.24
P/FCF	27.45 18.90

Indicator	TTM Median
ROE	35.17 24.62
ROA	14.38 6.73
ROI	23.55 9.85
Net Worth	564.08 0.21
Quick Ratio	0.77 1.72
Current Ratio	1.03 2.84

Indicator	TTM Median
Net Profit Margin	21.83 11.21
Operating Margin	25.88 14.57
Gross Margin	67.82 69.23
Return on tangible equity	0.00 54.38

Indicator	TTM Median
EPS	2.70 0.37
EPS Forecast	2.67 0.37
Revenue	24.06B 16.00M
Gross Profit	15.96B —
EBITDA	7.43B —

Johnson & Johnson

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue